Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - rosuvastatin calcium, quantity: 5.198 mg - tablet, film coated - excipient ingredients: mannitol; purified talc; macrogol 6000; lactose; hypromellose; microcrystalline cellulose; maize starch; colloidal anhydrous silica; sodium stearylfumarate; silicon dioxide; titanium dioxide; iron oxide yellow; iron oxide red - primary hypercholesterolaemia: rosuzet composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: - not appropriately controlled with rosuvastatin or ezetimibe alone; or - already treated with rosuvastatin and ezetimibe. homozygous familial hypercholesterolaemia (hofh): rosuzet composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - rosuvastatin calcium, quantity: 10.396 mg - tablet, film coated - excipient ingredients: hypromellose; sodium stearylfumarate; lactose; colloidal anhydrous silica; purified talc; maize starch; macrogol 6000; mannitol; microcrystalline cellulose; silicon dioxide; titanium dioxide; iron oxide yellow; iron oxide red - primary hypercholesterolaemia: ezalo composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: - not appropriately controlled with rosuvastatin or ezetimibe alone; or - already treated with rosuvastatin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh): ezalo composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - rosuvastatin calcium, quantity: 41.583 mg - tablet, film coated - excipient ingredients: lactose; microcrystalline cellulose; purified talc; hypromellose; colloidal anhydrous silica; maize starch; mannitol; macrogol 6000; sodium stearylfumarate; silicon dioxide; titanium dioxide; iron oxide yellow; iron oxide red - primary hypercholesterolaemia: ezalo composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: - not appropriately controlled with rosuvastatin or ezetimibe alone; or - already treated with rosuvastatin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh): ezalo composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - rosuvastatin calcium, quantity: 41.583 mg - tablet, film coated - excipient ingredients: macrogol 6000; hypromellose; mannitol; sodium stearylfumarate; maize starch; colloidal anhydrous silica; lactose; microcrystalline cellulose; purified talc; silicon dioxide; titanium dioxide; iron oxide yellow; iron oxide red - primary hypercholesterolaemia: rosuzet composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: - not appropriately controlled with rosuvastatin or ezetimibe alone; or - already treated with rosuvastatin and ezetimibe. homozygous familial hypercholesterolaemia (hofh): rosuzet composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

arthrex australia pty ltd - 45061 - fixation anchor, soft-tissue, biodegradable - biocomposite swivelock anchors are comprised of absorbable pla and tcp and are provided with a non-absorbable eyelet. it is a twist-in knotless device, consisting of an eyelet and anchor body that are pre-mounted and physically separated on a driver shaft. it is designed to provide necessary pull-out strength during the healing period. the biocomposite swivelock suture anchors are intended to be used for suture (soft tissue) fixation to bone in the foot, ankle, knee, hand, wrist, elbow, shoulder, and hip.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 41.6 mg (equivalent: rosuvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; crospovidone; light magnesium oxide; titanium dioxide; hypromellose; triacetin; iron oxide red - primary hypercholesterolaemia,ezecrest composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients:,? not appropriately controlled with rosuvastatin or ezetimibe alone; or ? already treated with rosuvastatin and ezetimibe,homozygous familial hypercholesterolaemia (hofh),ezecrest composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 41.6 mg (equivalent: rosuvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; crospovidone; light magnesium oxide; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide red - primary hypercholesterolaemia,pharmacor ezetimibe rosuvastatin composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients:,? not appropriately controlled with rosuvastatin or ezetimibe alone; or,? already treated with rosuvastatin and ezetimibe,homozygous familial hypercholesterolaemia (hofh),pharmacor ezetimibe rosuvastatin composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 20.8 mg (equivalent: rosuvastatin, qty 20 mg) - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; light magnesium oxide; lactose monohydrate; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide red - primary hypercholesterolaemia,ezecrest composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients:,? not appropriately controlled with rosuvastatin or ezetimibe alone; or ? already treated with rosuvastatin and ezetimibe,homozygous familial hypercholesterolaemia (hofh),ezecrest composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 20.8 mg (equivalent: rosuvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; light magnesium oxide; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide red - primary hypercholesterolaemia,pharmacor ezetimibe rosuvastatin composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients:,? not appropriately controlled with rosuvastatin or ezetimibe alone; or,? already treated with rosuvastatin and ezetimibe,homozygous familial hypercholesterolaemia (hofh),pharmacor ezetimibe rosuvastatin composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 10.4 mg (equivalent: rosuvastatin, qty 10 mg) - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; light magnesium oxide; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide red - primary hypercholesterolaemiapharmacor ezetimibe rosuvastatin composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients:,? not appropriately controlled with rosuvastatin or ezetimibe alone; or,? already treated with rosuvastatin and ezetimibe,homozygous familial hypercholesterolaemia (hofh),pharmacor ezetimibe rosuvastatin composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).